Blutdruckmedikamente – Welche Präparate sind bei Niereninsuffizienz anzuwenden?

Bluthochdruck ist bei Patienten mit eingeschränkter Nierenfunktion fast immer zu identifizieren. In der Regel sind antihypertensive Therapieregime notwendig, um den Blutdruck zu kontrollieren. Diese Kontrolle gelingt häufig nur in der Kombination von mehreren antihypertensiven Medikamenten. Bei der Niereninsuffizienz sind die pharmakologischen und pharmakodynamischen Eigenschaften vieler antihypertensiver Medikamente modifiziert und damit z. T. wirkungslos oder auch sogar kontraindiziert. In der vorliegenden Übersicht wird dargelegt, mit welchen Medikamenten bei den sehr unterschiedlichen Stadien der Nierenfunktionsstörungen behandelt werden kann und wie die aktuellen Empfehlungen der unterschiedlichen Hochdruckgesellschaften sind.

High blood pressure is often observed in patients with disturbances in renal function. Blood pressure medication is usually essential to control high blood pressure. Often, more than 2 different antihypertensive medications are necessary to control blood pressure. Due to renal functional disturbances, we have changes in pharmadynamic and pharmacological properties of the used medications. Many substances have no function at all with renal failure or they might get toxic properties. In the present review, we want to give an overview which medication can be used to control blood pressure in the very different kidney function situations. The current guidelines from various high blood pressure councils are summarized.

Key words

blood pressure - medication - drugs - renal insufficiency

• Literatur

• 1 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219
• 2 Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community a statement by the american society of hypertension and the international society of hypertension. J Hypertens 2014; 32: 3-15
• 3 James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520
• 4 Tobe SW, Clase CM, Gao P et al. ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123: 1098-1107
• 5 Bakris GL, Sarafidis PA, Weir MR et al. ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181
• 6 Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54: 889-896
• 7 Bakris GL, Weir MR, Secic M et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65: 1991-2002
• 8 Levin NW, Kotanko P, Eckardt KU et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2010; 77: 273-284
• 9 Inrig JK, Oddone EZ, Hasselblad V et al. Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients. Kidney Int 2007; 71: 454-461
• 10 Vonend O, Rump LC, Ritz E. Sympathetic overactivity--the Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial 2008; 21: 326-330
• 11 Heerspink HJ, Ninomiya T, Zoungas S et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015
• 12 Opelz G, Dohler B. Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725-2731
• 13 Opelz G, Zeier M, Laux G et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257-3262
• 14 Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-899
• 15 Rahn KH, Barenbrock M, Fritschka E et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354: 1415-1420
• 16 Kuypers DR, Neumayer HH, Fritsche L et al. Lacidipine Study Group. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 2004; 78: 1204-1211
• 17 Cross NB, Webster AC, Masson P et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7-18
• 18 Chapter 7: Blood pressure management in elderly persons with CKD ND. Kidney Int Suppl 2012; 2: 377-381